ArticleBMC health services research2025
The impact of National Volume-Based Procurement (NVBP) on healthcare expenditures for breast cancer outpatients: an interrupted time series analysis in Wuhan, China.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn January 2019, the Chinese government launched a pilot National Volume-Based Procurement (NVBP) program, which was then gradually extended to the whole country to alleviate the financial burden of healthcare expenditure. This study aims to investigate the impact of the NVBP policy on healthcare expenditure.
methodBy extracting outpatient payment records of breast cancer patients in a tertiary hospital information system from May 2020 to April 2023, we performed an interrupted time series (ITS) to assess the impact of the NVBP policy on healthcare expenditure.
resultsITS analyses showed that the NVBP policy mitigated the persistent increase in total average monthly per-visit expenditure, shifting it from an upward trend (9.68 CNY (p < 0.01)) to a flat trend (-2.33 CNY (p = 0.673)). The momentum of the continuous increase in the average monthly per-visit drug expenditure of patients has been effectively curbed; the expenditure has turned from an upward trend (15.10 CNY (p < 0.01)) to a downward trend (-11.19 CNY (p < 0.01)). Although the trend of continuous increase in average monthly per-visit expenditures for chemotherapy drugs (p < 0.01), oral endocrine drugs (p < 0.01) and Traditional Chinese Medicines (TCM) (p < 0.01) were effectively mitigated, especially for TCM; however, the expenditure of injectable endocrine drugs (p = 0.038), examination (p = 0.015) and laboratory (p = 0.029) were the persistent increases.
conclusionsOur study suggested that the NVBP policy effectively prevented the continued growth in drug expenditure for breast cancer outpatients, but did not substantially improve total expenditure. In addition, the policy has not only affected the expenditures of medicines, but has also changed the structure of expenditures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.